logo
The Best AI Software Developers in Chicago

The Best AI Software Developers in Chicago

Time Business News15 hours ago
Artificial intelligence is no longer a future bet—it's an urgent priority. From finance to healthcare to ecommerce, companies across Chicago are embracing AI to automate operations, personalize customer experiences, and unlock new streams of revenue. But the success of AI implementation depends on one critical factor: choosing the right development partner.
Chicago has become a hotbed for AI innovation, with local firms blending world-class technical talent, industry-specific expertise, and pragmatic software engineering. Whether you're a startup building an AI-powered product or an enterprise seeking to modernize your internal systems, the right AI software developer can accelerate your journey by months or even years.
In this guide, we've reviewed dozens of local consultancies and engineering firms to bring you a curated list of the best AI software development companies in Chicago. These aren't theory-heavy think tanks—they're execution-focused teams that know how to deploy AI in the real world. And at the top of our list sits a firm that has quietly become one of the city's most trusted names in applied artificial intelligence: Xcelacore.
Chicago's business landscape is uniquely suited to AI adoption. The city is home to leading institutions in healthcare, finance, logistics, and manufacturing—all industries that generate vast amounts of data and face complex operational challenges. AI, when applied correctly, can turn that data into decisions, predictions, and personalized experiences.
But AI success takes more than just access to data. It requires: Engineering discipline
Domain knowledge
Clean integration with existing tools
Ethical, explainable deployment
Long-term model monitoring
That's where Chicago-based AI developers excel. They bring not just technical capabilities, but a contextual understanding of the challenges unique to Midwestern industries. And they know how to build AI into the fabric of your systems—not just bolt it on.
When it comes to building AI that's reliable, secure, and actually useful, Xcelacore leads the way. Based in Oak Brook, just outside Chicago, Xcelacore has quietly built a reputation as the go-to engineering team for companies that want measurable AI results—not hype.
What sets Xcelacore apart is its focus on end-to-end delivery. They don't just prototype models—they create entire AI ecosystems that are secure, scalable, and integrated into your business processes. Their team combines data scientists, software engineers, cloud architects, and compliance experts who collaborate closely with clients throughout the build process.
Their AI work spans multiple industries. In healthcare, they've built predictive models that help hospitals identify high-risk patients—reducing readmission rates and improving outcomes. In fintech, they've developed AI agents for customer onboarding, fraud detection, and credit risk scoring, all designed with compliance in mind. And in manufacturing, they've helped clients implement AI for quality control and predictive maintenance, reducing costs and minimizing downtime.
But perhaps most importantly, Xcelacore doesn't disappear after launch. They stay on to monitor model performance, retrain when needed, and evolve your AI stack as your business grows. In an industry where many firms hand you a model and walk away, that kind of ongoing support is a game-changer.
If you're looking for a true AI development partner in Chicago—one that understands your goals, moves fast, and delivers real ROI—Xcelacore should be your first call.
Another standout in the Chicago tech scene is West Monroe, a nationally recognized consulting firm that merges business transformation with cutting-edge technology. Their approach to AI is highly strategic—focusing on how machine learning can fundamentally improve operations, customer service, and decision-making.
What makes West Monroe unique is their ability to bridge the gap between boardroom strategy and engineering execution. Their consultants work closely with business leaders to identify AI opportunities, build scalable models, and deploy them across complex enterprise environments. They've done extensive work in healthcare, energy, and financial services—often combining AI with cloud platforms and process redesign.
If you're looking to pair AI implementation with broader digital transformation goals, West Monroe offers the kind of executive alignment and industry depth that large enterprises need.
For large organizations with deep technical needs, Cognizant's Chicago office, bolstered by its TriZetto healthcare platform, is a formidable option. Cognizant is a global leader in managed AI services, data engineering, and automation—and its presence in Chicago includes major healthcare and financial services clients.
Cognizant excels at building massive AI systems that integrate with EMRs, claims processing tools, banking CRMs, and more. If your team is already invested in legacy infrastructure and you need a partner who can modernize without breaking everything, this is a great fit.
They're especially strong in compliance-heavy environments. For healthcare and finance firms navigating HIPAA, SOC 2, or PCI regulations, Cognizant's process maturity and security protocols can make the difference between approval and audit failure.
Slalom takes a different approach to AI—starting with the user experience. Their teams focus on embedding intelligence into digital products in a way that feels natural, helpful, and responsible. With a strong presence in Chicago and deep cloud expertise (especially AWS and Azure), Slalom helps companies create intelligent apps, bots, and interfaces that solve real problems.
Their design-first, agile approach makes them ideal for companies that want to experiment with AI in a controlled way—building pilots, testing features, and iterating based on user feedback. For teams launching their first AI-powered customer tools, Slalom can help you balance ambition with usability.
SPR, another Chicago-born firm, specializes in data engineering and machine learning operations (MLOps). They're not the flashiest on this list—but they are quietly building some of the most reliable AI backends in the city.
SPR's strength lies in their ability to handle complex pipelines, build sustainable model training workflows, and ensure that AI systems don't collapse under real-world data stress. They've done deep work in manufacturing, logistics, and utilities—where performance and uptime matter more than glossy interfaces.
If you already have a data team and need help with deployment, monitoring, and optimization, SPR brings the technical muscle to turn your models into production-ready systems.
Tandem is a boutique Chicago development shop known for rapid prototyping and lean product design. They bring startup energy to AI product development—helping companies test ideas, launch quickly, and pivot based on results.
They're ideal for teams building their first AI product or feature. Whether you're exploring chatbots, predictive tools, or integrations with OpenAI and LLMs, Tandem will help you go from concept to MVP without overbuilding.
Their developers and designers work side by side, which means your AI product will be not only functional—but also user-friendly.
If your company is in growth mode and needs help getting AI products into the hands of users fast, LaunchPad Lab is a strong choice. They've helped Chicago-area startups and midsize businesses build web apps, internal dashboards, and mobile tools powered by AI and machine learning.
Their team moves quickly and understands how to balance business priorities with technical risk. For companies looking to embed AI into customer experiences—like personalization engines, product recommendations, or smart search—LaunchPad Lab offers a lean, collaborative approach with fast results.
Deloitte's Chicago office is a powerhouse in digital transformation—and when it comes to AI, they bring global expertise backed by enterprise-grade infrastructure. While they often work with large, complex clients, their local teams are deeply embedded in the city's healthcare, financial, and public sector networks.
Deloitte excels at turning massive datasets into scalable, secure AI systems with clear KPIs and compliance baked in. They're ideal for organizations undergoing full-scale modernization and looking to use AI as part of a broader initiative.
Moove It is a newer player in Chicago's AI ecosystem but has quickly built a strong reputation for quality. Their focus is on building intelligent digital products with robust cloud infrastructure and modern design. Their clients include healthcare startups, fintech platforms, and logistics companies looking to create standout user experiences with AI at the core.
Their cross-functional teams cover everything from prompt engineering and UI to secure deployment and testing—making them a good fit for companies building AI-first applications.
Finally, Kohactive stands out for its ability to embed AI into full digital ecosystems. Rather than building standalone models, they help companies create web and mobile platforms that use AI to drive business logic, personalization, or analytics behind the scenes.
They're especially strong in API development and microservices—so if your goal is to extend AI across multiple systems or user touchpoints, Kohactive brings the technical coordination needed to make that work.
AI is a powerful tool—but only when it's implemented with care, context, and discipline. Chicago offers a diverse range of partners for AI software development, from enterprise giants to nimble product teams. Your success will depend on finding a team that aligns with your business goals, understands your industry, and knows how to deliver real outcomes—not just demos.
If you're looking for a trusted partner to guide you through the AI journey, from idea to execution and beyond, Xcelacore is our top recommendation. With unmatched experience across industries, a commitment to cost-effective delivery, and a proven track record of impact, they're the AI development firm that Chicago companies rely on when it matters most.
TIME BUSINESS NEWS
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Here's Why Omnicom (OMC) is a Strong Momentum Stock
Here's Why Omnicom (OMC) is a Strong Momentum Stock

Yahoo

time32 minutes ago

  • Yahoo

Here's Why Omnicom (OMC) is a Strong Momentum Stock

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike. Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular investing methodologies, namely value, growth, and momentum. The Style Scores can help you narrow down which stocks are better for your portfolio and which ones can beat the market over the long-term. Different than value or growth investors, momentum-oriented investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks. New York-based Omnicom is one of the largest advertising, marketing, and corporate communications companies in the world. The company's networks, practice areas, and agencies offer a comprehensive suite of services across global, pan-regional, and local levels, spanning the following fundamental disciplines: Media & Advertising, Precision Marketing, Public Relations, Healthcare, Branding & Retail Commerce, Experiential, and Execution & Support. These disciplines are areas of professional expertise or service within the broader field of marketing, communications, and advertising. OMC sits at a Zacks Rank #2 (Buy), holds a Momentum Style Score of A, and has a VGM Score of B. The stock is down 2.6% and up 4.7% over the past one-week and four-week period, respectively, and Omnicom has lost 22% in the last one-year period as well. Additionally, an average of 4,640,654 shares were traded over the last 20 trading sessions. A company's earnings performance is important for momentum investors as well. For fiscal 2025, two analysts revised their earnings estimate higher in the last 60 days for OMC, while the Zacks Consensus Estimate has increased $0.01 to $8.33 per share. OMC also boasts an average earnings surprise of 3.7%. OMC should be on investors' short list because of its impressive earnings fundamentals, a good Zacks Rank, and strong Momentum and VGM Style Scores. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Omnicom Group Inc. (OMC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research

Sino Biopharma spends $951m to acquire China-based LaNova Medicines
Sino Biopharma spends $951m to acquire China-based LaNova Medicines

Yahoo

time39 minutes ago

  • Yahoo

Sino Biopharma spends $951m to acquire China-based LaNova Medicines

Hong Kong-listed Sino Biopharmaceutical will acquire China-based oncology specialist LaNova Medicines in a deal that will not exceed $951m, representing one of the largest transactions within the Asia-Pacific pharmaceutical arena this year. Sino already owns a 4.91% stake courtesy of an investment in November 2024, with the company now seeking to purchase the remaining 95.09% it does not own. At the time, Sino spent 142 million yuan ($19.80m) to initiate its ownership involvement with the biotech. The net payment made by Sino to acquire LaNova will be approximately $500.9m, a figure that excludes the estimated cash and bank deposits, according to a company document outlining the terms of the transaction. Following the completion of the nearly billion-dollar deal, LaNova Medicines will become an indirect wholly owned subsidiary of Sino. A timeline of 30 business days has been set by the companies to finalise the deal. Sino revealed the acquisition agreement after trading hours on 15 July. The share price in the company had climbed 3.6% by market close. LaNova's drug development focuses on tumour immunity and the tumour microenvironment. The company has particular emphasis on antibody-drug conjugates (ADCs) and has built several platforms within this modality. Sino stated the acquisition would strengthen its research and development capabilities, subsequently enhancing competitiveness and innovation in the oncology market. LaNova's pipeline has already been raided twice by US big pharma companies. In 2023, AstraZeneca licensed LM-305, a G-protein targeting-ADC, for $600m. A year later, MSD outlaid more than $3bn to secure global rights to LM-299, an anti-PD-1/VEGF bispecific antibody. According to Sino, LaNova Medicines has two projects in the registration clinical stage, six projects in the Phase I/II clinical trial stage, and more than ten projects in the preclinical research stage. In a statement, Sino said: 'Through the in-depth synergy and integration of the advantageous resources of both parties, not only will the potential value of LaNova Medicines be fully released, but also [Sino's] innovation capability will be comprehensively enhanced." The company added that the transaction will help towards its 'strategic goal of advancing towards a world-class innovative pharmaceutical enterprise'. China's economy grew 5.2% year-on-year in Q2, defying the lingering effects of US President Trump's trade war and reinforcing its position as the world's top exporter. This economic resilience is mirrored in China's growing role in the global oncology market. Despite economic pressures, licensing promising drug candidates from Chinese biotechs is becoming a well-trodden path for many US big pharma companies. Licensing deals between US and Chinese biopharma companies hit record highs last year, a 280% increase from 2020, according to analysis by GlobalData. Across big pharma, transactions rose 66% from $16.6bn in 2023 to $41.5bn in 2024, demonstrating that China is still the go-to place to discover pipeline candidates. For deals specific to US companies, the analysis found that total deal value rose from $15.7bn in 2023 to $21.3bn in 2024. GlobalData is the parent company of Pharmaceutical Technology. "Sino Biopharma spends $951m to acquire China-based LaNova Medicines" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store